Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab, high-dose cytarabine and dexamethasone followed by BEAM in mantle cell lymphoma <66 years
2011-004039-30Phase 2Terminated
- Sponsor
- University Hospitals Plymouth
- Start
- Feb 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, cytarabine, dexamethasone, carmustine, etoposide and 1 more in mantle cell lymphoma (MCL), sponsored by University Hospitals Plymouth. Primary endpoint: Complete remission pre-transplant. Started Feb 2012; status: terminated.
02
Drugs
rituximabcytarabinedexamethasonecarmustineetoposide
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2011-004039-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004039-30.